Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, Hubei, 430022, China.
Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, 430022, China.
Adv Sci (Weinh). 2023 Dec;10(35):e2303215. doi: 10.1002/advs.202303215. Epub 2023 Oct 31.
Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a highly efficacious treatment modality for refractory and relapsed hematopoietic malignancies in recent years. Furthermore, CAR technologies for cancer immunotherapy have expanded from CAR-T to CAR-natural killer cell (CAR-NK), CAR-cytokine-induced killer cell (CAR-CIK), and CAR-macrophage (CAR-MΦ) therapy. Nevertheless, the high cost and complex manufacturing processes of ex vivo generation of autologous CAR products have hampered broader application. There is an urgent need to develop an efficient and economical paradigm shift for exploring new sourcing strategies and engineering approaches toward generating CAR-engineered immune cells to benefit cancer patients. Currently, researchers are actively investigating various strategies to optimize the preparation and sourcing of these potent immunotherapeutic agents. In this work, the latest research progress is summarized. Perspectives on the future of CAR-engineered immune cell manufacturing are provided, and the engineering approaches, and diverse sources used for their development are focused upon.
近年来，嵌合抗原受体 T 细胞（CAR-T）疗法已成为治疗难治性和复发性血液系统恶性肿瘤的一种非常有效的治疗方法。此外，癌症免疫疗法的 CAR 技术已经从 CAR-T 扩展到 CAR-自然杀伤细胞（CAR-NK）、CAR-细胞因子诱导的杀伤细胞（CAR-CIK）和 CAR-巨噬细胞（CAR-MΦ）疗法。然而，自体 CAR 产品的体外生成的高成本和复杂制造过程限制了其更广泛的应用。因此，迫切需要开发一种高效且经济的范式转变，以探索新的来源策略和工程方法来生成 CAR 工程免疫细胞，从而使癌症患者受益。目前，研究人员正在积极研究各种策略来优化这些强效免疫治疗药物的制备和来源。本工作总结了最新的研究进展。并提供了对 CAR 工程免疫细胞制造未来的展望，重点介绍了它们的工程方法和开发中使用的不同来源。
